RecruitingRecruiting
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
NCT07843485 · Hoffmann-La Roche
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide vs. Placebo in Participants With Overweight or Obesity and Type 2 Diabetes
About this study
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and with Type 2 Diabetes (T2D).
Eligibility criteria
Inclusion Criteria:
* Participants with BMI ≥ 27 kg/m²
* T2D diagnosis as per World Health Organization (WHO) classification (or other locally applicable standards) with HbA1c ≥ 6.5% to ≤ 10% (48-86 mmol/mol), measured by the central laboratory at screening
* Stable treatment with either diet and exercise alone, basal insulin, or selected oral glucose-lowering agents, for at least 90 days prior to and during screening
* History of at least one self-reported unsuccessful dietary effort to lose body weight
Exclusion Criteria:
* History or presence of proliferative diabetic retinopathy, or diabetic macular edema
* Current or previous treatment with petrelintide or any other amylin analog
Study design
Enrollment target: 600 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-10-09
Estimated completion: 2029-01-19
Last updated: 2026-11-05
Interventions
Combination Product: PetrelintideCombination Product: Placebo
Primary outcomes
- • Percentage Change in Body Weight from Baseline (From Baseline to Week 64)
Sponsor
Hoffmann-La Roche · industry
With: Zealand Pharma
Contacts & investigators
ContactReference Study ID Number: CC46369 https://forpatients.roche.com/No attachments to email below. · contact · global-roche-genentech-trials@gene.com · 888-662-6728 (U.S. and Canada)
ContactFastest Response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry · contact
All locations (2)
Institute for Metabolic Research Los AngelesRecruiting
Los Angeles, California, United States
Manassas Clinical Research CenterRecruiting
Manassas, Virginia, United States